Welcome to the e-CCO Library Archive!
P411
Four-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
C. Cassieri*1, R. Pica1, E. v. V. Avallone1, G. Brandimarte2, M. Zippi1, P. Crispino1, G. Lecca2, C. Corrado1, P. Vernia1, P. Paoluzi1, E. v. S. Corazziari1
1 ‘Sapienza’ University, Internal Medicine and Medical Specialties, Rome, Italy, 2’Cristo Re’ Hospital, Internal Medicine, Rome, Italy
P412
Evolution of patients with ulcerative colitis who withdraw the maintenance treatment with mesalazine
A. Algaba*, I. Guerra, D. Bonillo, M. Hernández, A. Granja, P. Bernal, F. Berrmejo
Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain
P413
Endoscopic balloon dilatation of Crohn’s strictures is safe and effective in selected cases
A. Asairinachan*, V. An, E. Daniel, M. Johnston, J. Keck, P. Salama, R. Woods
St Vincent’s Hospital Melbourne, Victoria, Australia
Abstract has been withdrawn.
P414
Usefulness of ultrasonography in the assessment of postoperative recurrence of Crohn’s disease
M. Murakami*1, T. Kanemura1, A. Haga1, R. Kubota1, K. Yaguchi1, M. Nishio1, S. Tsuda1, T. Ogashiwa1, Y. Kogure1, K. Kasahara1, K. Hirai2, Y. Fukuno2, M. Jin2, A. Hanzawa2, H. Yonezawa2, K. Sakamaki3, K. Numata4, H. Kimura1, R. Kunisaki1
1Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan, 2Yokohama City University Medical Centre, Department of Laboratory Medicine and Clinical Investigation, Yokohama, Japan, 3Graduate School of Medicine, Yokohama City University, Department of Biostatistics and Epidemiology, Yokohama, Japan, 4Yokohama City University Medical centre, Gastroenterology Centre, Yokohama, Japan
P415
Therapeutic drug monitoring of thiopurines in the management of Asian patients with inflammatory bowel disease
S. N. W. Chuah*1, P. Delord2, N. Sutiman3, W. F. Leong3, S. C. Kong1, B. Schwender1, P. W. Chan1, H. H. Shim1, E. Salazar1, E. H. Ong4, H. Y. Aw5, J. L. Hartono4, W. C. Lim6, C. Ong7, P. L. Ong8, K. L. Ling1, B. Chowbay2
1Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 2National Cancer Centre, Clinical Pharmacology Laboratory, Singapore, Singapore, 3Singapore Health Services, Clinical Pharmacology, Singapore, Singapore, 4National University Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 5National University Hospital, Division of Paediatric Gastroenterology, Singapore, Singapore, 6Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 7KK Women’s and Children’s Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 8Changi General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore
P416
An online educational portal is effective in improving knowledge regarding reproduction and IBD
K. Wierstra1, K. Smith1, J. Bal2, L. Ambrosio2, K. I. Kroeker2, L. Dieleman2, B. Halloran2, R. N. Fedorak2, K.-A. Berga3, V. W. Huang*4
1University of Alberta, Edmonton, Canada, 2University of Alberta, Gastroenterology, Edmonton, Canada, 3MacEwan University, Edmonton, Canada, 4University of Alberta, Medicine, Edmonton, Canada
P417
Ulcerative colitis: let’s talk about extent
A. Vaz*, M. Eusébio, A. Antunes, P. Queirós, T. Gago, T. Belo, P. Caldeira, H. Guerreiro
Centro Hospitalar do Algarve, Faro, Portugal
P418
Ulcerative colitis and end-stage liver disease in children with primary sclerosing cholangitis
P. Czubkowski*, M. Wozniak, J. Pawlowska, I. Jankowska, J. Kierkus
The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland
P419
Efficacy of vedolizumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodies
C. Höög*, M. Eberhardson, S. Almer
Karolinska Institute, Stockholm, Sweden
P420
Does vedolizumab change mural vascularisation in ulcerative colitis and is there a correlation with endoscopic findings?
D. Klett*, D. Strobel, D. Wildner, R. Atreya, M. F. Neurath, R. S. Görtz
Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany
P421
Skin side effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseases
K. Juzlova1, K. Koblova1, J. Herzogova1, M. Bortlik*2, D. Duricova2, M. Lukas2
12nd Faculty of Medicine, Charles University, Department of Dermatovenereology, Prague, Czech Republic, 2Charles University, IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic
P422
Risks and clinical features of active tuberculosis developed in patients with inflammatory bowel disease receiving anti-tumour necrosis factor therapy
J. W. Lee, C. H. Choi*
Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea
P423
Paediatric Crohn’s disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumab
C. Olbjørn*1, 2, J. B. Rove1, J. Jahnsen2, 3
1Akershus University Hospital, Department of Paediatric and Adolescent Medicine, Lørenskog, Norway, 2University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 3Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway
P424
Surgery for children with Crohn’s disease.
M. Stefanowicz*1, H. Ismail1, G. Kowalewski1, A. Kowalski1, J. Kierkuś2, P. Kaliciński1
1Children’s Memorial Health Institute, Department of Paediatric Surgery and Organ Transplantations, Warszawa, Poland, 2Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warszawa, Poland
P425
Comparison of therapeutic choices in biologic experienced Crohn’s disease and ulcerative colitis patients in Europe: discontinuation rates because of disease improvements
A. Franceschetti*1, A. Baskett2, H. McKenzie2
1Ipsos healthcare, London, United Kingdom, 2Ipsos Healthcare, London, United Kingdom
P426
Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn’s disease
E. Zittan*1, 2, O. B. Kelly1, B. Kabakchiev1, G. C. Nguyen1, K. Croitoru1, A. H. Steinhart1, M. S. Silverberg1
1Mount Sinai Hospital, Zane Cohen Centre for Digestive Diseases; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada, 2Institute of Gastroenterology and Liver Diseases, Emek Medical Centre, Afula, Israel
P427
The real-life experience of vedolizumab efficacy and safety in Crohn’s disease: a prospective observational multicentre cohort study
A. Amiot*1, J. C. Grimaud2, X. Treton3, J. Filippi4, B. Pariente5, L. Peyrin-Biroulet6, A. Noureille7, A. Buisson8, F. Carbonnel9, A. Bourrier10, S. Nancey11, X. Roblin12, P. Marteau13, R. Altwegg14, J. Moreau15, A. Aubourg16, G. Savoye17, A. L. Pelletier18, M. Fumery19, B. Bonaz20, Y. Bouhnik3
1Henri Mondor Hospital, Gastroenterology, Creteil, France, 2Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, 3APHP Beaujon, Department of Gastroenterology, Clichy, France, 4Archet 2 Hospital, Department of Gastroenterology, Nice, France, 5CHRU Lille, Department of Gastroenterology, Lille, France, 6CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, 7CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, 8CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, 9CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France, 10APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, 11Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, 12University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, 13Hospital Lariboisière, Department of Gastroenterology, Paris, France, 14CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, 15CHU de Toulouse Hospital de Rangueil, Department of Gastroenterology, Toulouse, France, 16Chu Tours, Department of Gastroenterology and Hepatology, Tours, France, 17CHU Rouen, Department of Gastroenterology, Rouen, France, 18Hospital Bichat Claude Bernard, Department of Gastroenterology, Paris, France, 19Amiens University Hospital, Department of Gastroenterology, Amiens, France, 20Grenoble, gastroenterologie, Grenoble, France
P428
Tofacitinib pharmacokinetics and durability of drug exposure in moderate-to-severe Crohn’s disease patients in Phase 2 induction and maintenance studies
A. Mukherjee1, C. Deng2, R. Xie2, S.W. Martin3, G. Chan4, M. Moscariello4, W. Niezychowski4, E. Maller*4
1Pfizer Inc, Groton, United States, 2Pfizer Inc, Shanghai, China, 3Pfizer Inc, Cambridge, United States, 4Pfizer Inc, Collegeville, Pennsylvania, United States
P429
The effects of psychiatric treatment in patients with inflammatory bowel disease: a prospective study
O. Yanartas1, H. c. T. Kanı2, E. Bicakci3, Y. Bez1, M. Banzragch3, Z. Senkal1, I. Kilic4, O. Atug3, K. Kuscu1, N. Imeryuz3, H. Akin*3
1Marmara University, Psychiatry, Istanbul, Turkey, 2Marmara University, Internal Medicine, Istanbul, Turkey, 3Marmara University, Gastroenterology, Istanbul, Turkey, 4Marmara University, Medical Student, Istanbul, Turkey
P430
Prognostic significance of serial faecal calprotectin in inflammatory bowel disease
Y. Zhulina1, Y. Cao2, K. Amcoff3, M. Carlson3, C. Tysk1, J. Halfvarson*1
1Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, 2Örebro University, Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health, Örebro, Sweden, 3Uppsala University, Department of Medical sciences, Gastroenterology Research Group, Uppsala, Sweden